Leptin receptor polymorphisms and lung function decline in COPD

European Respiratory Journal

Volumn 34, Issue 1, 2009, Pages 103-110

  Hansel, N N ^a   Gao, L ^a   Rafaels, N M ^a   Mathias, R A ^c   Neptune, E R ^a   Tankersley, C ^b   Grant, A V ^a   Connett, J ^d   Beaty, T H ^b   Wise, R A ^a   Barnes, K C ^a,b,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Leptin receptor; Lung function decline; Polymorphisms

Indexed keywords

LEPTIN RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INBRED STRAIN; LUNG; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANIMALS; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MICE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, LEPTIN;

EID: 69249113434     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00120408     Document Type: Article

References (37)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 2002; 47: 1184-1199.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
3. O'Donnell CP, Tankersley CG, Polotsky VP, et al. Leptin, obesity, and respiratory function. Respir Physiol 2000; 119: 163-170.
4. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243-1252.
5. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-759.
6. Calikoglu M, Sahin G, Unlu A, et al. Leptin and TNF-α levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration 2004; 71: 45-50.
7. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1239-1245.
8. Schols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1220-1226.
9. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65.
10. Madiehe AM, Mitchell TD, Harris RB. Hyperleptinemia and reduced TNF-a secretion cause resistance of db/db mice to endotoxin. Am J Physiol Regul Integr Comp Physiol 2003; 284: R763-R770.
11. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
12. Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-845.
13. Bruno A, Chanez P, Chiappara G, et al. Does leptin play a cytokine-like role within the airways of COPD patients? Eur Respir J 2005; 26: 398-405.
14. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364.
15. Wedzicha JA. Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1757-1758.
16. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635.
17. Tsuchiya T, Shimizu H, Horie T, et al. Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol 1999; 365: 273-279.
18. Guerassimov A, Hoshino Y, Takubo Y, et al. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004; 170: 974-980.
19. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
20. Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999; 106: 410-416.
21. Enright PL, Connett JE, Kanner RE, et al. Spirometry in the Lung Health Study: II. Determinants of short-term intraindividual variability. Am J Respir Crit Care Med 1995; 151: 406-411.
22. Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996; 153: 1802-1811.
23. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
24. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
25. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
26. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
27. Thompson DB, Ravussin E, Bennett PH, et al. Structure and sequence variation at the human leptin receptor gene in lean and obese Pima Indians. Hum Mol Genet 1997; 6: 675-679.
28. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
29. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
30. Zhang YY, Gottardo L, Mlynarski W, et al. Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis 2007; 191: 121-127.
31. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853.
32. Takabatake N, Nakamura H, Minamihaba O, et al. A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. Am J Respir Crit Care Med 2001; 163: 1314-1319.
33. Broekhuizen R, Vernooy JH, Schols AM, et al. Leptin as local inflammatory marker in COPD. Respir Med 2005; 99: 70-74.
34. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008; 294: L612-L631.
35. Brusselle GG, Bracke KR, Maes T, et al. Murine models of COPD. Pulm Pharmacol Ther 2006; 19: 155-165.
36. Shapiro SD, Demeo DL, Silverman EK. Smoke and mirrors: Mouse models as a reflection of human chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 929-931.
37. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 1999; 21: Suppl. 1, 48-50.